Growth Metrics

Gilead Sciences (GILD) Cash & Equivalents Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 14.21%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 4.20%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 11.85%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -18.13%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -27.48%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 15.61%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -7.70%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 2.10%
10 Gsk 88.34 Bn 83.66 Bn - 1.15%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 15.61%
Dec 31, 2025 11.81%
Sep 30, 2025 15.98%
Jun 30, 2025 2.77%
Mar 31, 2025 22.65%
Dec 31, 2024 23.24%
Sep 30, 2024 4.91%
Jun 30, 2024 -17.26%
Mar 31, 2024 5.09%
Dec 31, 2023 0.49%
Sep 30, 2023 -23.78%
Jun 30, 2023 -5.44%
Mar 31, 2023 -21.10%
Dec 31, 2022 -22.51%
Sep 30, 2022 -20.84%
Jun 30, 2022 -25.02%
Mar 31, 2022 -36.69%
Dec 31, 2021 -33.24%
Sep 30, 2021 -33.10%
Jun 30, 2021 -28.23%
Mar 31, 2021 -18.98%
Dec 31, 2020 -7.54%
Sep 30, 2020 3.84%
Jun 30, 2020 -8.17%
Mar 31, 2020 -0.76%
Dec 31, 2019 12.23%
Sep 30, 2019 -1.15%
Jun 30, 2019 20.12%
Mar 31, 2019 38.91%
Dec 31, 2018 11.76%
Sep 30, 2018 1.42%
Jun 30, 2018 21.29%
Mar 31, 2018 -10.43%
Dec 31, 2017 -8.87%
Sep 30, 2017 22.84%
Jun 30, 2017 -0.07%
Mar 31, 2017 17.11%
Dec 31, 2016 57.33%
Sep 30, 2016 69.60%
Jun 30, 2016 43.34%
Mar 31, 2016 50.19%
Dec 31, 2015 92.41%
Sep 30, 2015 108.05%
Jun 30, 2015 65.86%
Mar 31, 2015 94.21%
Dec 31, 2014 0.48%
Sep 30, 2014 89.71%
Jun 30, 2014 112.82%
Mar 31, 2014 51.66%
Dec 31, 2013 32.52%
Sep 30, 2013 25.26%
Jun 30, 2013 14.10%
Mar 31, 2013 25.77%
Dec 31, 2012 12.32%
Sep 30, 2012 14.81%
Jun 30, 2012 16.02%
Mar 31, 2012 -4.44%